SAGE Working Group on influenza vaccines and immunization (established August 2010)
Terms of Reference
Objectives of the Working Group:
- Prepare for a SAGE evidence-based review and updating of WHO recommendations on the use of seasonal influenza vaccine (e.g. priority target groups) with a particular focus on low and middle-income countries and with a view to update the 2005 WHO influenza vaccine position papers.
- Prepare for a SAGE discussion on coverage goals for seasonal influenza vaccination to be proposed to the WHA to update the coverage goals contained in the 2003 resolution.
- Identify essential gaps in evidence that may impede SAGE's ability to update the recommendations on the use of influenza vaccines and propose coverage targets.
- Provide advice about pandemic vaccine preparedness.
- Elizabeth Miller, Chair of Working Group. Health Protection Agency, United Kingdom
- Jon Abramson, Wake Forest University School of Medicine, United States of America
- Art Reingold, University of California, United States of America. (Joined the Working Group after the SAGE meeting in November 2010)
- Claire-Anne Siegrist, University of Geneva, Switzerland
- William Kwabena Ampofo, Noguchi Memorial Institute for Medical Research, Ghana
- Joseph Bresee, Centers of Disease Control, United States of America
- Janet Englund, Seattle Children’s Hospital, United States of America
- Randeep Guleria, All India Institute of Medical Sciences, India
- Yu Hongjie, Chinese Center for Disease Control and Prevention, People's Republic of China
- Michael Pfleiderer, Paul-Ehrlich-Institut, Germany
- David Salisbury, Department of Health, United Kingdom
- Barry Schoub, National Institute for Communicable Diseases, South Africa
- John Tam
- Philippe Duclos
- Cuauhtémoc Ruiz-Matus
- Nahoko Shindo, replaced by Anthony Mounts in October 2011
DECLARATION OF INTERESTS FOR WHO EXPERTS
All Working Group members completed a declaration of interests.
Four members reported relevant interests. All interests were assessed not to constitute a conflict of interest. It was concluded that all members could take part in full in all of the discussions. The reported relevant interests are summarized below:
• Her department received funding from MedImmune, Novartis, Adamas, ADMA Bio, BioCRYST and Sanofi Pasteur for conducting research in respiratory virology, meningococcal vaccines, influenza therapies, diphtheria-tetanus-pertussis trivalent vaccines and human respiratory syncytial virus immunotherapy. However none of the studies focused on influenza vaccines and immunization which was the subject of the meeting. These interests were assessed as non-personal, non-specific and financially significant*.
• Received a small honorarium from GlaxoSmithKline and Macrae group for a one-time participation in an influenza external experts speaker bureau meeting. This interest was assessed as personal, specific and financially insignificant*.
• Sits on a scientific committee in his Institute's annual Congress on Vaccinology and has received small travel and accommodation grants from Sanofi Pasteur. This interest was assessed as personal, non-specific and financially insignificant*.
Claire-Anne Siegrist :
• Her university receives funding from Sanofi Pasteur, NasVax Ltd and DBV Technologies for conducting research in vaccine adjuvants and seroepidemiology of pneumococcal infections. Until 2008, her university also received research funding from GlaxoSmithKline to study pertussis antibodies. None of the studies focused on influenza vaccines and immunization which is the subject of the Working Group. These interests were assessed as non-personal, non-specific and financially significant*.
• Developed and owns the Viavac immunization management software destined to support Swiss health care professionals to follow the official immunization recommendations. Her ownership in the enterprise generates royalties of less than 10,000 USD per annum. This interest was assessed as personal, non-specific and financially significant*.
• Received partial travel grants from Sanofi Pasteur and Wyeth to attend scientific meetings on pneumococcal vaccines. These interests were assessed as personal, non-specific and financially insignificant*.
• Until 2009, received a small honoraria from GlaxoSmithKline for vaccinology training of pediatricians. This interest was assessed as personal, non-specific and financially insignificant*.
* According to WHO's Guidelines for Declaration of Interests (WHO expert), an interest is considered "personal" if it generates financial or non-financial gain to the expert, such as consulting income or a patent. "Specificity" states whether the declared interest is a subject matter of the meeting or work to be undertaken. An interest has "financial significance" if the honoraria, consultancy fee or other received funding, including those received by expert's organization, from any single vaccine manufacturer or other vaccine-related company exceeds 10,000 USD in a calendar year. Likewise, a shareholding in any one vaccine manufacturer or other vaccine-related company in excess of 1,000 USD would also constitute a “significant shareholding”.
Last updated: 18 November 2011
Last updated: 18 November 2011